Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.18B P/E - EPS this Y -192.80% Ern Qtrly Grth -
Income -153.61M Forward P/E -7.69 EPS next Y 24.80% 50D Avg Chg -10.00%
Sales 371.21M PEG 0.06 EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 2.25 EPS next 5Y -200.40% 52W High Chg -37.00%
Recommedations 2.40 Quick Ratio 17.47 Shares Outstanding 80.28M 52W Low Chg 36.00%
Insider Own 1.43% ROA -6.22% Shares Float 79.19M Beta 1.78
Inst Own 66.81% ROE -8.17% Shares Shorted/Prior 14.72M/14.87M Price 53.01
Gross Margin -39.43% Profit Margin -41.38% Avg. Volume 1,274,458 Target Price 87.57
Oper. Margin 34.58% Earnings Date Feb 21 Volume 1,470,467 Change -6.03%
About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP Chatroom

User Image martinasevic Posted - 6 hours ago

$CRSP sell put on this position. It’s very profitable we will recover on a long-term.

User Image chartsmarter Posted - 6 hours ago

FULL BIOTECH GAME PLAN UP: https://www.chartsmarter.com/2024/03/28/healthcare-sector-review-4-1-24/ "once a month we show what we do daily. XBI needs to hold above very round 90 number. $IOVA reclaims 21-day EMA, $BPMC eyeing par, $AGIO puts in doji candle Thursday." $CRSP $BEAM TWST OSCR #biotech #StockMarket

User Image InYourFaceTomSelleck Posted - 8 hours ago

$CRSP this is a long hold. I'm not worried. I'll buy more if it reaches 65

User Image codingispower Posted - 9 hours ago

$CRSP When's ER?

User Image swingtrader910 Posted - 10 hours ago

$CRSP eyeing 63 for a big big add

User Image DoctrBenway Posted - 10 hours ago

$CRSP Small add @ 67.8

User Image HamburgerTim Posted - 10 hours ago

$CRSP what a dog

User Image Franki5250 Posted - 11 hours ago

$CRSP man they punished crsp this thing touched 90 last month wtf

User Image Kelly12 Posted - 11 hours ago

$CRSP buy here?

User Image BarneyR Posted - 11 hours ago

$CRSP Scummy MMs squeezing shareholders for shares. Hanging onto mine, thanks.

User Image Do_The_Opposite Posted - 11 hours ago

$CRSP $BEAM Short these 2 and load up on Editas $EDIT

User Image Diefreeandsell Posted - 11 hours ago

$MDGL $IBRX $ALT $LXRX $CRSP IOVA TGTX To all my Friends and Frenemies! HAPPY GOOD FRIDAY and HAPPY EASTER Enjoy the gathering with your families and friends !!

User Image Sigh_why Posted - 11 hours ago

$FOUR want to get in here and $CRSP soon

User Image 4Mathias Posted - 11 hours ago

$CRSP been adding aggressively here

User Image SlyDelvecchio Posted - 11 hours ago

$CRSP I need powder!

User Image BeenHereTooLong Posted - 12 hours ago

$CRSP Unrelenting every day.

User Image tkstockpicker Posted - 12 hours ago

$CRSP added back a little more

User Image KcWatermark73 Posted - 12 hours ago

$CRSP what about this? Is there news yet?

User Image Medo55 Posted - 12 hours ago

$CRSP A great discount week for a company with a promising future

User Image JasonCO Posted - 12 hours ago

$CRSP lot of meat on this bone

User Image TheInvestoGator Posted - 12 hours ago

$CRSP That’s a nice tree ya got there. Be a shame if someone came along and shook it to death.

User Image GREENDAY_2000 Posted - 12 hours ago

$CRSP March was such a great month :( That extra leap year day started the shit show from 90 down to 67. Maybe hitting support level around 66.

User Image HarryScrotmsRashy Posted - 13 hours ago

$CRSP my god how many days in a row has this gone down. If Cathy don't buy no one else does.

User Image 3rdratesherlock Posted - 13 hours ago

$CRSP I'd be tempted to add some contracts to my dragons hoard worth of shares, but if it breaks down a bit Ill be pissed at myself. Ill risk missing an add.

User Image Anee98 Posted - 13 hours ago

$CRSP waiting for $62 to load Jan 26 options

User Image portroyal1 Posted - 13 hours ago

$CRSP okay, my tax lady called, and my taxes r done. Adding next week. Please stay low for me!

User Image 4Mathias Posted - 14 hours ago

$CRSP Vertex Will in the next days give an update on casgevy launch 👏🏻

User Image classhopper Posted - 15 hours ago

$CRSP living the buy now on CRSP NVDA and META

User Image Coinviction Posted - 15 hours ago

$CRSP 110c 1/26 🧬

User Image codingispower Posted - 15 hours ago

$CRSP Well damn, bought at 70...smh...should have waited until today.

Analyst Ratings
Mizuho Buy Mar 6, 24
Morgan Stanley Underweight Feb 26, 24
RBC Capital Sector Perform Feb 22, 24
Wells Fargo Equal-Weight Feb 22, 24
Barclays Equal-Weight Feb 22, 24
Chardan Capital Buy Feb 22, 24
Needham Buy Feb 21, 24
Wolfe Research Peer Perform Feb 15, 24
RBC Capital Sector Perform Dec 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jan 29 Sell 60.8 50,000 3,040,000 187,377 01/31/24
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jan 29 Option 19.12 50,000 956,000 237,377 01/31/24
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer May 30 Sell 65.13 25,000 1,628,250 387,377 06/01/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer May 30 Option 19.12 25,000 478,000 412,377 06/01/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Apr 25 Sell 50.97 25,000 1,274,250 387,377 04/27/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Apr 25 Option 19.12 25,000 478,000 412,377 04/27/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Mar 29 Sell 44.58 25,000 1,114,500 387,377 03/31/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Mar 29 Option 19.12 25,000 478,000 412,377 03/31/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Feb 27 Sell 48.49 25,000 1,212,250 375,988 03/01/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Feb 27 Option 19.12 25,000 478,000 400,988 03/01/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jan 27 Sell 51.07 25,000 1,276,750 369,111 01/31/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jan 27 Option 19.12 25,000 478,000 394,111 01/31/23
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Dec 28 Sell 41.13 25,000 1,028,250 369,111 12/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Dec 28 Option 19.12 25,000 478,000 394,111 12/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Dec 06 Option 1.81 58,233 105,402 369,111 12/08/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Nov 28 Option 19.12 25,000 478,000 315,279 11/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Nov 28 Sell 54.61 25,000 1,365,250 290,279 11/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Sep 28 Option 16.21 25,000 405,250 315,279 09/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Sep 28 Sell 64.77 25,000 1,619,250 290,279 09/30/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Aug 29 Option 16.21 25,000 405,250 315,279 08/31/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Aug 29 Sell 66.92 25,000 1,673,000 290,279 08/31/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jul 27 Option 14.39 25,000 359,750 315,279 07/29/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jul 27 Sell 76.63 25,000 1,915,750 290,279 07/29/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jun 29 Option 12.57 25,000 314,250 315,279 07/01/22
Kulkarni Samarth Chief Executive Offi.. Chief Executive Officer Jun 29 Sell 61.87 25,000 1,546,750 290,279 07/01/22